Travere Therapeutics Inc - TVTX STOCK NEWS

Travere Therapeutics (TVTX) announced strong performance in its fourth quarter and full year 2020 financial results, with net product sales increasing by 13% year-over-year to $198 million. The company reported a net loss of $121.6 million for Q4 2020, compared to $30.3 million in Q4 2019. Key developments include achieving the interim endpoint in the DUPLEX Study for FSGS and plans to report data from the PROTECT Study for IgAN in Q3 2021. The company’s cash position stands at $361.6 million, boosted by a recent stock offering generating $189 million in proceeds.

Travere Therapeutics (NASDAQ: TVTX) participates in Rare Disease Day 2021, honoring over 400 million individuals worldwide affected by rare diseases. CEO Eric Dube emphasizes their commitment to improving patient outcomes and community access to treatment. The company supports various organizations tackling healthcare inequities and promoting innovation in rare diseases. The National Burden of Rare Disease Study, expected to release economic impact findings on February 25, aims to raise awareness and inform policy changes. Travere will host an internal event on February 26 to celebrate this initiative.

Travere Therapeutics (NASDAQ: TVTX) has announced its participation in two upcoming virtual investor conferences. The first is the SVB Leerink 10th Annual Global Healthcare Conference on February 24, 2021, at 1:00 p.m. ET. The second is the Barclays Global Healthcare Conference on March 10, 2021, at 11:30 a.m. ET. Live webcasts and archived replays will be available for 30 days on their website. Travere focuses on developing therapies for rare diseases, engaging with the community to understand their needs and deliver impactful treatments.

Travere Therapeutics (NASDAQ: TVTX) has received orphan designation from the European Commission for sparsentan, targeting IgA nephropathy (IgAN), a rare kidney disorder that can lead to end-stage kidney disease. Sparsentan, currently in pivotal Phase 3 trials for both IgAN and focal segmental glomerulosclerosis (FSGS), achieved its interim proteinuria endpoint in the DUPLEX Study. The company aims to set a new treatment standard for IgAN and indicates positive early results. Orphan designation grants a 10-year marketing exclusivity and various incentives in the EU.

Travere Therapeutics has completed an underwritten public offering of 7,532,500 shares of its common stock at $26.75 per share, raising approximately $201.5 million in gross proceeds. The offering included 982,500 shares from the full exercise of underwriters’ options. The shares were sold under an effective shelf registration statement filed with the SEC. The offering was managed by BofA Securities, Jefferies, and SVB Leerink.

Travere Therapeutics (NASDAQ: TVTX) will announce its fourth quarter and full year 2020 financial results on March 1, 2021, after U.S. market close. A conference call will follow at 4:30 p.m. ET to discuss these results and provide a business update. The call can be accessed via dial-in or live webcast, with a replay available for a week post-call. Travere is focused on developing therapies for rare diseases, emphasizing its commitment to patient needs and insights.

Travere Therapeutics (Nasdaq: TVTX) has announced the pricing of a public offering of 6,550,000 shares of common stock at $26.75 per share, aiming to raise approximately $175.2 million. The offering is set to close on February 17, 2021, pending customary closing conditions. Underwriters hold an option to purchase an additional 982,500 shares within 30 days. Major banks involved include BofA Securities, Jefferies, and SVB Leerink, with the company's shares available through a previously filed SEC registration statement.

Travere Therapeutics (Nasdaq: TVTX) announced plans to offer $150 million in common stock through an underwritten public offering. This offering includes a 30-day option for underwriters to buy an additional 15% of shares. The offering is subject to market conditions, and the actual terms remain uncertain. BofA Securities, Jefferies, and SVB Leerink serve as joint book-running managers. The shares will be sold under a previously filed shelf registration statement effective since September 4, 2018.

Travere Therapeutics (NASDAQ: TVTX) announced that the FDA has granted Orphan Drug Designation for sparsentan to treat IgA nephropathy, a rare kidney disorder. This designation supports the development of sparsentan, which is currently in Phase 3 trials, aimed at addressing the unmet medical needs of IgAN patients. The Company anticipates topline data from interim assessments in 2021. Orphan Drug Designation enhances incentives for clinical trials and may provide seven years of market exclusivity if approved.